Skin field
On sale
Autologous cultured epidermis
| Indications: | Severe burns |
|---|---|
| Status: | approval obtained in October 2007, insurance coverage from January 2009 |
| Notes: | Japan's 1st regenerative medical product |
On sale
Autologous cultured epidermis
| Indications: | Congenital giant pigmented nevus [Expansion of Indication] |
|---|---|
| Status: | indication expanded in September 2016, insurance coverage from December 2016 |
On sale
Autologous cultured epidermis
| Indications: | Epidermolysis bullosa [Expansion of Indication] |
|---|---|
| Status: | indication expanded in December 2018, insurance coverage from July 2019 |
On sale
Autologous cultured epidermis with melanocytes
| Indications: | Vitiligo |
|---|---|
| Status: | approval obtained in March 2023, insurance coverage from October 2024 |
In development
Allogeneic cultured epidermis
| Indications: | Second-degree burns |
|---|---|
| Status: | submitted clinical trial notification in November 2021, conducting clinical trial developing as national / AMED project |
Cartilage field
On sale
Autologous cultured cartilage
| Indications: | Traumatic cartilage defect or osteochondritis dissecans |
|---|---|
| Status: | approval obtained in July 2012, insurance coverage from April 2013 |
| Notes: | Japan's 2nd regenerative medical product |
In development
Autologous cultured cartilage
| Indications: | Knee osteoarthritis [Expansion of indication] |
|---|---|
| Status: | submitted a request of approval to include knee osteoarthritis in June 2024 |
Ophthalmology field
On sale
Autologous cultured corneal epithelium
| Indications: | Corneal epithelial stem cell deficiency |
|---|---|
| Status: | approval obtained in March 2020, insurance coverage from June 2020 |
| Notes: | 1st regenerative medical product in Ophthalmology field in Japan |
On sale
Autologous cultured oral mucosal epithelium
| Indications: | Corneal epithelial stem cell deficiency |
|---|---|
| Status: | approval obtained in June 2021, insurance coverage from December 2021 |
| Notes: | 2nd regenerative medical product in Ophthalmology field in Japan |
Cancer field
In development
Autologous CAR-T cells
| Indications: | CD19-positive acute lymphocytic leukaemia, malignant lymphoma |
|---|---|
| Status: | Nagoya University is conducting clinical research |